Cancer immunoediting by the innate immune system in the absence of adaptive immunity
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Cancer immunoediting is the process whereby immune cells protect against cancer formation by sculpting the immunogenicity of developing tumors. Although the full process depends on innate and adaptive immunity, it remains unclear whether innate immunity alone is capable of immunoediting. To determine whether the innate immune system can edit tumor cells in the absence of adaptive immunity, we compared the incidence and immunogenicity of 3'methylcholanthrene-induced sarcomas in syngeneic wild-type, RAG2(-/-), and RAG2(-/-)x γc(-/-) mice. We found that innate immune cells could manifest cancer immunoediting activity in the absence of adaptive immunity. This activity required natural killer (NK) cells and interferon γ (IFN-γ), which mediated the induction of M1 macrophages. M1 macrophages could be elicited by administration of CD40 agonists, thereby restoring editing activity in RAG2(-/-)x γc(-/-) mice. Our results suggest that in the absence of adaptive immunity, NK cell production of IFN-γ induces M1 macrophages, which act as important effectors during cancer immunoediting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In line with these findings, microbes may reverse the resistance to immunotherapy through reactivation of IFN-ɤ signaling pathways.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“IFN-ɤ, an important cytokine involved in antitumor immunity, could upregulate MHC expression on tumor cells and M1 macrophages and facilitate the recognition and elimination of transformed cells (91, 92).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…for macrophages that is consistent with studies performed almost 40 yr ago, when it was shown that activated macrophages from infected mice (Hibbs et al., 1971) could kill syngeneic transformed murine embryonic fibroblasts, but not primary nontransformed murine embryonic fibroblasts (Hibbs…”
BackgroundTakahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“Using the 3 methylcholanthrene (MCA) model of sarcomagenesis, we previously found that the immune system in WT mice could edit tumors more effectively than the immune system in RAG2 / mice (which lack adaptive immunity; Shankaran et al., 2001; Takahashi and Yamanaka, 2006), but we did not assess whether tumors from RA…”
MethodCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citationMonocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190 · cited 4×
“M1 macrophages are activated classically via IFN- and function in the removal of intracellular pathogens (Gordon and Taylor, 2005).”
BackgroundResultInfluentialThe Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · cited 13×
“Tumor induction by MCA was performed as previously described (Smyth et al., 2000; Shankaran et al., 2001).”
BackgroundMethodResultInfluentialSelf-citationAlternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 1×
“…characterized by quantitative PCR, using markers known to be associated with an M1-type phenotype (TNF and inducible nitric oxide synthase [iNOS]; Martinez et al., 2009) or with an M2-type phenotype (arginase and epithelial cadherin [eCAD]), growth arrest–specific gene 3 (Gas3; Ghassabeh et al.,…”
MethodDistinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225 · cited 2×
“…that these macrophages were classically activated (Gordon and Taylor, 2005) M1 macrophages and performed immunophenotyping to detect the presence of tumor-associated M1 or M2 macrophages, known to have anti- or pro-tumor functions, respectively (Lewis and Pollard, 2006; Sica et al., 2008).”
BackgroundRAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,150 · cited 1×
“Genotyping was performed using PCR (for IL-2R c, following The Jackson Laboratories protocol [http://jaxmice.jax.org/strain/003174.html]) or by Southern blot for RAG2 (Shinkai et al., 1992).”
Method
Cited by
Items 101–200 of 348
The Ugly Duckling Turned to Swan: A Change in Perception of Bystander-Activated Memory CD8 T Cells
Maurice, N. J., Taber, A. K., & Prlic, M. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000937 · Cited by 61
“NKG2D-mediated killing by NK cells and IFNγ secretion by either tumor Ag-specific T cells and NK cells can contribute to solid tumor clearance (88, 89).”
NK Cells Control Tumor-Promoting Function of Neutrophils in Mice
Ogura, K., Sato‐Matsushita, M., Yamamoto, S., Hori, T., Sasahara, M., Iwakura, Y., Saiki, I., Tahara, H., & Hayakawa, Y. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0204 · Cited by 65
Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond
Pagliuca, S., Gurnari, C., Rubio, M., Visconte, V., & Lenz, T. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944872 · Cited by 62
Kratochvill, F., Gratz, N., Qualls, J. E., Van De Velde, L.-A., Chi, H., Kovarik, P., & Murray, P. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0205 · Cited by 56
“Tracing tools argue that population "A" gives rise to the Ly6Cþ, MHCIIþpopulation "B,"which thendevelops into themature "C" fraction, consisting of cells that downregulate Ly6C and increase expression of MHCII (22, 23).”
InfluentialWhy natural killer cells in triple negative breast cancer?
Abdel-Latif, M., & Youness, R. A. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i7.464 · Cited by 57
Imam, S., Dar, P., Paparodis, R. D., Almotah, K., Al-Khudhair, A., Hasan, S. A., Salim, N., & Jaume, J. C. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0483-y · Cited by 59
Hamaïdia, M., Gazon, H., Hoyos, C., Hoffmann, G. B., Louis, R. E., Duysinx, B., & Willems, L. (2019) · JCI Insight · doi:10.1172/jci.insight.128474 · Cited by 59
Cash, H. A., Shah, S., Moore, E. C., Caruso, A. M., Uppaluri, R., Waes, C. V., & Allen, C. T. (2015) · Oncotarget · doi:10.18632/oncotarget.5063 · Cited by 57
Self-citationBrom, V. C., Burger, C., Wirtz, D. C., & Schildberg, F. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837645 · Cited by 57
Mekky, R. Y., Ragab, M. F., Manie, T., Attia, A. A., & Youness, R. A. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101653 · Cited by 51
Mechanical stretch promotes tumoricidal M1 polarization via the FAK/NF‐κB signaling pathway
Shan, S., Fang, B., Zhang, Y., Wang, C., Zhou, J., Niu, C., Gao, Y., Zhao, D., He, J., Wang, J., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900799rr · Cited by 58
Deng, Y., Chu, J., Ren, Y., Fan, Z., Ji, X., Mundy-Bosse, B. L., Yuan, S., Hughes, T. L., Zhang, J., Cheema, B. S., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302600 · Cited by 56
Tumor-Primed NK Cells: Waiting for the Green Light
Sabry, M., & Lowdell, M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00408 · Cited by 45
Bandini, S., Curcio, C., Macagno, M., Quaglino, E., Arigoni, M., Lanzardo, S., Hysi, A., Barutello, G., Consolino, L., Longo, D. L., et al. (2013) · OncoImmunology · doi:10.4161/onci.26137 · Cited by 53
“The highly immunosuppressive tumor microenvironment of neuT-C3 carcinomas may be instrumental for their escape from the immune system and immunoediting.(48) Accordingly, we observed that neuT-C3 carcinoma cells display impaired growth upon transplantation into syngeneic immunocompetent BALB/c mice.”
Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology
Saito, R., Kobayashi, T., Kashima, S., Matsumoto, K., & Ogawa, O. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01520-z · Cited by 56
IL-17D: A Less Studied Cytokine of IL-17 Family
Liu, X., Sun, S., & Liu, D. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000508255 · Cited by 51
Lim, C. Y., Chang, J. H., Lee, W. S., Kim, J., & Park, I. Y. (2021) · Gut and Liver · doi:10.5009/gnl210311 · Cited by 52
Natural killer cells and type 1 innate lymphoid cells in cancer
Lopes, N., Vivier, É., & Narni-Mancinelli, É. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2022.101709 · Cited by 52
Klinke, D. J. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003409 · Cited by 49
Cell-cell fusion as a mechanism of DNA exchange in cancer
Searles, S. C., Santosa, E. K., & Bui, J. D. (2017) · Oncotarget · doi:10.18632/oncotarget.23715 · Cited by 47
Self-citationBeta-1,6 glucan converts tumor-associated macrophages into an M1-like phenotype
Cheng, H., Sun, L., Shen, D., Ren, A. H., Ma, F., Tai, G., Fan, L., & Zhou, Y. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116715 · Cited by 45
The role of opioids in cancer response to immunotherapy
Botticelli, A., Cirillo, A., Pomati, G., Cerbelli, B., Scagnoli, S., Roberto, M., Gelibter, A. J., Mammone, G., Calandrella, M. L., Cerbelli, E., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02784-8 · Cited by 51
Kondratova, M., Czerwińska, U., Sompairac, N., Amigorena, S., Soumelis, V., Barillot, E., Zinovyev, A. Y., & Kuperstein, I. (2019) · Nature Communications · doi:10.1038/s41467-019-12270-x · Cited by 53
Wu, T., Tang, C., Tao, R., Yong, X., Jiang, Q., & Feng, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693881 · Cited by 49
Patel, R. B., Baniel, C., Sriramaneni, R. N., Bradley, K. A., Markovina, S. T., & Morris, Z. S. (2018) · Brachytherapy · doi:10.1016/j.brachy.2018.07.004 · Cited by 49
Deng, S., Clowers, M. J., Velasco, W. V., Ramos-Castaneda, M. A., & Moghaddam, S. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01556 · Cited by 45
Gumbleton, M., Sudan, R., Fernandes, S., Engelman, R. W., Russo, C. M., Chisholm, J. D., & Kerr, W. G. (2017) · Science Signaling · doi:10.1126/scisignal.aam5353 · Cited by 43
Liu, Z., Ding, M., Qiu, P., Pan, K., & Guo, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1200282 · Cited by 46
The Adaptive Complexity of Cancer
Derbal, Y. (2018) · BioMed Research International · doi:10.1155/2018/5837235 · Cited by 45
Bouzidi, L., Triki, H., Charfi, S., Kridis, W. B., Derbel, M., Ayadi, L., Sellami‐Boudawara, T., & Cherif, B. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.02.003 · Cited by 44
Habanjar, O., Diab‐Assaf, M., Caldefie‐Chezet, F., & Delort, L. (2022) · Biology · doi:10.3390/biology11020339 · Cited by 45
Torregrosa, C., Chorin, F., Beltran, E. E. M., Neuzillet, C., & Cardot‐Ruffino, V. (2022) · Cancers · doi:10.3390/cancers14215402 · Cited by 55
Sharma, N., Fan, X., Atolagbe, O. T., Ge, Z., Dao, K., Sharma, P., & Allison, J. P. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231263 · Cited by 43
“…al., 2006; Zhu et al., 2014), TAMs exhibit significant plasticity and can polarize into M1-like phenotypes under specific conditions (Wang et al., 2010; O ’ Sullivan et al., 2012; Biswas and Mantovani, 2010; Mantovani et al., 2002; Guiducci et al., 2005; Saccani et al., 2006; Stout et al., 2009).”
BackgroundImmune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice
Carlino, F., Diana, A., Piccolo, A., Ventriglia, A., Bruno, V., Santo, I. D., Letizia, O., Vita, F. D., Daniele, B., Ciardiello, F., et al. (2022) · Cancers · doi:10.3390/cancers14092102 · Cited by 44
Molecular landscape of immune pressure and escape in aplastic anemia
Pagliuca, S., Gurnari, C., Hercus, C., Hergalant, S., Nadarajah, N., Wahida, A., Terkawi, L., Mori, M., Zhou, W., Visconte, V., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01723-w · Cited by 43
Cancer immunoediting hypothesis: history, clinical implications and controversies
Lasek, W. (2022) · Central European Journal of Immunology · doi:10.5114/ceji.2022.117376 · Cited by 55
Казакова, А., Sudarskikh, T., Kovalev, O. I., Kzhyshkowska, J. G., & Larionova, I. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5480 · Cited by 38
Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells
Dulphy, N., Chrétien, A.-S., Khaznadar, Z., Fauriat, C., Nanbakhsh, A., Caignard, A., Chouaïb, S., Olive, D., & Toubert, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00094 · Cited by 44
Valdés-Ferrada, J., Muñoz‐Durango, N., Pérez‐Sepúlveda, A., Muñiz, S., Coronado-Arrázola, I., Acevedo, F., Soto, J. A., Bueno, S. M., Sanchez, C. G., & Kalergis, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01413 · Cited by 40
Lieberman, N. A. P., DeGolier, K., Haberthur, K., Chinn, H. K., Moyes, K. W., Bouchlaka, M. N., Walker, K. L., Capitini, C. M., & Crane, C. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00150 · Cited by 38
Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
Stolk, D. A., van der Vliet, H. J., de Gruijl, T. D., van Kooyk, Y., & Exley, M. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01990 · Cited by 34
Heterogeneity of Cholangiocarcinoma Immune Biology
Vita, F., Olaizola, I., Amato, F., Rae, C. J., Marco, S., Bañales, J. M., & Braconi, C. (2023) · Cells · doi:10.3390/cells12060846 · Cited by 41
Papa, V., Pomi, F. L., Borgia, F., Vaccaro, M., Pioggia, G., & Gangemi, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097956 · Cited by 40
Pessina, S., Cantini, G., Kapetis, D., Cazzato, E., Ianni, N. D., Finocchiaro, G., & Pellegatta, S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1108513 · Cited by 33
Rationale for immunological approaches to breast cancer therapy
Monnot, G., & Romero, P. J. (2017) · The Breast · doi:10.1016/j.breast.2017.06.009 · Cited by 37
Immunosurveillance and Immunoediting of Breast Cancer via Class I MHC Receptors
Tu, M. M., Rahim, M. M. A., Sayed, C., Mahmoud, A. B., & Makrigiannis, A. P. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0056 · Cited by 34
Ai, R., Yan, T., Hao, Y., Jiang, L., Dan, H., Ji, N., Zeng, X. Y., Zhou, Y. J., & Chen, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.20312 · Cited by 37
Kasamatsu, J., Azuma, M., Oshiumi, H., Morioka, Y., Okabe, M., Ebihara, T., Matsumoto, M., & Seya, T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400924 · Cited by 36
Cancer Stem Cells (CSCs) in melanoma: There's smoke, but is there fire?
Brinckerhoff, C. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25796 · Cited by 33
Influence of Innate Immunity on Cancer Cell Stemness
Pastò, A., Consonni, F. M., & Sica, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093352 · Cited by 34
In vitro inhibition of tumor growth by low-dose iron oxide nanoparticles activating macrophages
Zhang, L., Tan, S., Liu, Y., Xie, H., Luo, B., & Wang, J. (2019) · Journal of Biomaterials Applications · doi:10.1177/0885328218817939 · Cited by 31
Killing the Invaders: NK Cell Impact in Tumors and Anti-Tumor Therapy
Molgora, M., Cortez, V. S., & Colonna, M. (2021) · Cancers · doi:10.3390/cancers13040595 · Cited by 33
Advances in natural killer cell therapies for breast cancer
Kiaei, S. Z. F., Nouralishahi, A., Ghasemirad, M., Barkhordar, M., Ghaffari, S., Kheradjoo, H., Saleh, M., Mohammadzadehsaliani, S., & Molaeipour, Z. (2023) · Immunology and Cell Biology · doi:10.1111/imcb.12658 · Cited by 33
Kmieciak, M., Payne, K. K., Wang, X., & Manjili, M. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082544 · Cited by 30
IFNγ in combination with IL-7 enhances immunotherapy in two rat glioma models
Fritzell, S., Eberstål, S., Sandén, E., Visse, E., Darabi, A., & Siesjö, P. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.02.017 · Cited by 36
Henrich, I. C., Jain, K., Young, R., Quick, L., Lindsay, J. M., Park, D. H., Oliveira, A. M., Blobel, G. A., & Chou, M. M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1458 · Cited by 30
Nemunaitis, M. B. J. (2013) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000209 · Cited by 29
Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis
Gross, E. T. E., Han, S., Vemu, P. L., Peinado, C. D., Maršala, M., Ellies, L. G., & Bui, J. D. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1268310 · Cited by 28
Self-citationFan, X., Jin, J., Yan, L., Liu, L., Li, Q., & Xu, Y. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108551 · Cited by 30
Microenvironment in the pathogenesis of gastric cancer metastasis
Sawayama, H., Ishimoto, T., & Baba, H. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.79 · Cited by 38
Harnessing Natural Killer Cells for Lung Cancer Therapy
Ma, S., Caligiuri, M. A., & Yu, J. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1097 · Cited by 28
Tumor border sharpness correlates with HLA-G expression in low-grade gliomas
Wang, Y., Fan, X., Li, H., Lin, Z., Bao, H., Li, S., Wang, L., Jiang, T., Fan, Y., & Jiang, T. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.02.013 · Cited by 28
“Human leukocyte antigen-G (HLA-G) is a non-classical MHC class I molecule, which is rarely detected in normal tissues (O'Sullivan et al., 2012; Vesely and Schreiber, 2013), and is broadly expressed in pathological situations, such as transplants, autoimmune diseases, infectious diseases, and cancers (Amiot et al.”
Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
Melero, I., Ochoa, M. C., Molina, C., Sánchez‐Gregorio, S., Garasa, S., Luri‐Rey, C., Hervás‐Stubbs, S., Casares, N., Elizalde, E., Gomis, G., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317804 · Cited by 27
“There is strong evidence for the importance of NK cells in the control of tumors (O’Sullivan et al , 2012; Wolf et al , 2023) and thus, NK cell-based immunotherapies have been extensively explored in many cancer types (Lamers-Kok et al , 2022).”
BackgroundImmunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?
Rolfo, C. D., Sortino, G., Smits, E., Passiglia, F., Bronte, G., Castiglia, M., Russo, A. D., Santos, E. S., Janssens, A., Pauwels, P., et al. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.952287 · Cited by 27
“In the first phase, the tumor’s growth induces the release of cytokines, which activates cells of the innate compartment (NK, gd-cells and macrophages) and makes them interact with tumor’s surface destroying its cells [7].”
Tumor-Derived PGE2 Gives NK Cells a Headache
Knudsen, N. H., & Manguso, R. T. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.018 · Cited by 26
Wang, Q., Sun, L., Yang, X., Ma, X., Li, Q., Chen, Y., Liu, Y., Zhang, D., Li, X., Xiang, R., et al. (2016) · Scientific Reports · doi:10.1038/srep27295 · Cited by 30
Kitahata, Y., Kanuma, T., Hayashi, M., Kobayashi, N., Ozasa, K., Kusakabe, T., Temizoz, B., Kuroda, E., Yamaue, H., Coban, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10379 · Cited by 27
Purbey, P. K., Seo, J., Paul, M. K., Iwamoto, K. S., Daly, A. E., Feng, A., Champhekar, A. S., Langerman, J., Campbell, K. M., Schaue, D., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114289 · Cited by 29
“8 IFN-γ is mainly produced by T helper cells, cytotoxic T cells, and natural killer (NK) cells, 4,7,9 while IFN-I is typically produced by dendritic cells (DCs) within the tumor microenvironment (TME).”
BackgroundImmunotherapy in the Battle Against Bone Metastases: Mechanisms and Emerging Treatments
Hamza, F. N., & Mohammad, K. S. (2024) · Pharmaceuticals · doi:10.3390/ph17121591 · Cited by 29
Stasikowska‐Kanicka, O., Wągrowska‐Danilewicz, M., & Danilewicz, M. (2017) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12657 · Cited by 27
A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro
Lei, X., Liu, C., Azadzoi, K. M., Li, C., Lu, F., An, X., Sun, J., Guo, Y., Zhao, Q., Yan, Z., et al. (2015) · Scientific Reports · doi:10.1038/srep07824 · Cited by 25
Narasimhan, P. B., Akabas, L. H., Tariq, S., Huda, N., Bennuru, S., Sabzevari, H., Hofmeister, R., Nutman, T. B., & Semnani, R. T. (2018) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0006404 · Cited by 26
Shi, L., Li, K., Guo, Y., Banerjee, A., Wang, Q., Lorenz, U. M., Parlak, M., Sullivan, L. C., Onyema, O. O., Arefanian, S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804931115 · Cited by 25
Microenvironmental Targets in Sarcoma
Ehnman, M., & Larsson, O. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00248 · Cited by 26
The Hepatic Pre-Metastatic Niche
Ormseth, B., Onuma, A. E., Zhang, H., & Tsung, A. (2022) · Cancers · doi:10.3390/cancers14153731 · Cited by 30
Tumor-expressed IL-17D recruits NK cells to reject tumors
Saddawi‐Konefka, R., O’Sullivan, T. E., Gross, E. T. E., Washington, A., & Bui, J. D. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954853 · Cited by 24
Self-citationSTAT3 governs the HIF-1α response in IL-15 primed human NK cells
Coulibaly, A., Velásquez, S. Y., Kassner, N., Schulte, J., Barbarossa, M. V., & Lindner, H. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-84916-0 · Cited by 27
Pérez‐Díez, A., Liu, X., & Matzinger, P. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0052 · Cited by 23
Tumor metabolism rewiring in epithelial ovarian cancer
Wang, M., Zhang, J., & Wu, Y. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01196-0 · Cited by 33
Intratumoral Heterogeneity in Lung Cancer
Lv, X., Mao, Z., Sun, X., & Liu, B. (2023) · Cancers · doi:10.3390/cancers15102709 · Cited by 31
Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG
Alderson, K. L., Luangrath, M. A., Elsenheimer, M. M., Gillies, S. D., Navid, F., Rakhmilevich, A. L., & Sondel, P. M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1372-8 · Cited by 23
“Previous studies from our laboratory [9] and others [30] have shown that interferon-c (IFNc) is required for macrophage activation in certain mouse models of tumor immunotherapy.”
Barakat, R., Chatterjee, J., Mu, R., Qi, X., Gu, X., Smirnov, I., Cobb, O. M., Gao, K., Barnes, A., Kipnis, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54569-4 · Cited by 27
Liebelt, B. D., Finocchiaro, G., & Heimberger, A. B. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00010-4 · Cited by 24
Chen, H., Sun, Q., Zhang, C., She, J., Cao, S., Cao, M., Zhang, N., Ayarick, V. A., Zhong, J., Yao, C., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.756085 · Cited by 22
Bücklein, V., Adunka, T., Mendler, A. N., Issels, R. D., Subklewe, M. S., Schmollinger, J. C., & Noeßner, E. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1178421 · Cited by 24
Chaudhuri, A., Wilson, N. S., Yang, B., Paler-Martínez, A., Liu, J., Zhu, C. Y., Bricker, N., Couto, S. S., Modrusan, Z. D., French, D. M., et al. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.27 · Cited by 21
Innate Lymphoid Cell Immunometabolism
O’Sullivan, T. E., & Sun, J. C.-Y. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.08.014 · Cited by 23
Self-citationSaddawi‐Konefka, R., Simon, A. B., Sumner, W., Sharabi, A. B., Mell, L. K., & Cohen, E. E. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.738626 · Cited by 22
Self-citationDomínguez‐Romero, A. N., Zamora-Alvarado, R., Servín-Blanco, R., Pérez-Hernández, E. G., Castrillón-Rivera, L. E., Munguía, M. E., Acero, G., Govezensky, T., Gevorkian, G., & Manoutcharian, K. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29679 · Cited by 19
NK cells propagate T cell immunity following in situ tumor vaccination
Jin, W. J., Jagodinsky, J. C., Vera, J. M., Clark, P. A., Zuleger, C., Erbe, A. K., Ong, I. M., Lе, T., Tetreault, K., Berg, T. J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113556 · Cited by 23
Diverse Roles of DEAD/DEAH-Box Helicases in Innate Immunity and Diseases
Perčulija, V., & Ouyang, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814685-9.00009-9 · Cited by 25
An evolutionary perspective on anti-tumor immunity
Klinke, D. J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2012.00202 · Cited by 20
Drak2 is not required for tumor surveillance and suppression
Edwards, B. A., Harris, T. L., Floersh, H., Lukens, J. R., Zaki, H., Vogel, P., Kanneganti, T., Bui, J. D., & McGargill, M. A. (2015) · International Immunology · doi:10.1093/intimm/dxu146 · Cited by 18
Self-citationElaraby, E., Malek, A. I., Abdullah, H. W., Elemam, N. M., Saber-Ayad, M. M., & Talaat, I. M. (2021) · Journal of Immunology Research · doi:10.1155/2021/9972927 · Cited by 21
The Growing Relevance of Immunoregulation in Pediatric Brain Tumors
Melcher, V., & Kerl, K. (2021) · Cancers · doi:10.3390/cancers13225601 · Cited by 19
Ager, C. R., Obradović, A., Arriaga, J. M., Chaimowitz, M. G., Califano, A., Abate-Shen, C. T., & Drake, C. G. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0637 · Cited by 18
Optimising IL-2 for Cancer Immunotherapy
Sprent, J., & Boyman, O. (2024) · Immune Network · doi:10.4110/in.2024.24.e5 · Cited by 20
The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies
Zhu, W., Fan, C., Zhao, Y., Li, W., Niu, J., Dong, S., Yang, Z., & Zhou, W. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03980-y · Cited by 19
“Sch-reiber et al. pioneered an immunomodulatory paradigm that underscores the proactive role of NK cells in combating early metastatic dissemination through hematogenous spread, rather than during the more mature stages of tumor clonality [225].”
Awasthi, B. P., Guragain, D., Chaudhary, P., Jee, J., Kim, J., & Jeong, B. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110255 · Cited by 18
Sánchez-León, M. L., Jiménez‐Cortegana, C., Silva-Romeiro, S., Garnacho, C., de la Cruz‐Merino, L., García-Domínguez, D. J., Hontecillas‐Prieto, L., & Sánchez‐Margalet, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065208 · Cited by 19
Metadata
- Authors
- O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., Smyth, M. J., Schreiber, R. D., & Bui, J. D.
- Affiliations
- University of California San Diego (US)
- Department of Pathology, University of California at San Diego, La Jolla, CA 92093 1
- University of Brescia (IT)
- Washington University in St. Louis (US)
- Center for Immunology, Department of Pathology and Immunology 3 and 4
- The University of Melbourne (AU)
- Corresponding author
- Bui, Jack D.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2012-08-27
- Volume
- 209
- Issue
- 10
- Pages
- 1869-1882
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3457735
- OpenAlex
- W2144577255
- Cited by
- 348
- References
- 58
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 24 · 2023: 31 · 2022: 22 · 2021: 30 · 2020: 29 · 2019: 25 · 2018: 32 · 2017: 30 · 2016: 27 · 2015: 23 · 2014: 21 · 2013: 29 · 2012: 6
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, public-domain)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Funders
- Cancer Research Institute
- Concern Foundation
- Hartwell Foundation (CA157885)
- Ludwig Institute for Cancer Research
- Cancer Research Coordinating Committee
- National Institutes of Health (CA157885)
- Medical Research Council
- National Health and Medical Research Council
- National Cancer Institute (CA 107527, CA128893, K08CA128893, K08CA090403, R01CA043059, R01CA157885, CA-43059, R37CA043059, R01CA107527, CA157885)
- National Center for Research Resources (C06RR012466)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer immunoediting, innate immunity, natural killer cells, interferon-gamma, M1 macrophages, CD40 agonist, Rag2 knockout mice, tumor immunogenicity, adaptive immunity
- MeSH terms
- Animals, Histocompatibility Antigens Class II, DNA-Binding Proteins, Immunity, Innate, Interferon-gamma, Killer Cells, Natural, Macrophages, Neoplasms, Phenotype, Sarcoma, Transplantation, Isogeneic, Mice, Knockout, CD40 Antigens, Genetic Predisposition to Disease, Cell Line, Tumor, Mice, Interleukin Receptor Common gamma Subunit, Adaptive Immunity, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.